NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/20/2026 12:53
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization167.89 mln
Float3.82 mln
Earnings Date08/17/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
64
/ 100
Outperforming
Debt / Equity
0.00
Debt-free
ROE
-412
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Indaptus Therapeutics is a New York-based clinical-stage company focused on developing treatments that use the immune system to fight cancer and viral infections. Its primary drug candidate, Decoy20, is being studied as both a standalone therapy and in combination with other treatments for several serious conditions, including multiple cancer types such as lymphoma, colorectal, liver, and pancreatic tumors, as well as chronic hepatitis B and HIV. The company was previously called Intec Parent Inc. before adopting its current name in August 2021.
